

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: S. V. Govindan

Title: STABLE RADIOIODINE CONJUGATES AND METHODS FOR THEIR SYNTHESIS

Appl. No.: Unassigned

Filing Date: 11/17/2003

Examiner: Unassigned

Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicant submits herewith on Form PTO-1449 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/605,873, filed 06/29/2000.

Applicant also submits Form PTO-892 listing documents cited by the Examiner in the parent application. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Nov. 17, 2003

By 

FOLEY & LARDNER  
Customer Number: 22428  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

Stephen B. Maebius  
Attorney for Applicant  
Registration No. 35,264

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>Date Submitted: November 17, 2003 (use as many sheets as necessary)</p>				<p><b>Complete if Known</b></p>	
Sheet	1	of	2	Application Number	Unassigned
				Filing Date	11/17/03
				First Named Inventor	S. V. Govindan
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	018733-1317

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A6	Goldenberg, D. M., "Monoclonal Antibodies in Cancer Detection and Therapy," <i>The American Journal of Medicine</i> , (March 1993) 94:297-312.	
	A7	Strobel, J. L. <i>et al.</i> , "I-Glycoconjugate Labels for Identifying Sites of Protein Catabolism <i>in Vivo</i> : Effect of Structure and chemistry of Coupling to Protein on Label Entrapment in Cells after Protein Degradation," <i>Archives of Biochemistry and Biophysics</i> , (August 1985) 240(2):635-645.	
	A8	Franano, F. N. <i>et al.</i> , "Metabolism of Receptor Targeted <sup>111</sup> In-DTPA-Glycoproteins: Identification of <sup>111</sup> In-DTPA- $\alpha$ -lysine as the Primary Metabolic and Excretory Product," <i>Nucl Med. Biol</i> (1994) 21(8):1023-1034.	
	A9	Dumas, P. <i>et al.</i> , "Spécificité de L'iiodotyrosine Desiodase des Microsomes Thyroïdiens et Hepatiques," <i>Biochimica et Biophysica Acta</i> (1973) 293:36-47.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Unassigned
Date Submitted: November 17, 2003 (use as many sheets as necessary)				Filing Date	11/17/03
				First Named Inventor	S. V. Govindan
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	018733-1317

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A10	Seham, A. A. et al., "Improving the Tumor Retention of Radioiodinated Antibody: Aryl Carbohydrate Adducts," <i>Cancer Research</i> (Suppl.) (February 1990) 50:783-788.	
	A11	Pawlak-Byczkowska, E. J. et al., "Two New Monoclonal Antibodies, EPB-1 and EPB-2, Reactive with Human Lymphoma," <i>Cancer Research</i> (August 1989) 49:4568-4577.	
	A12	Wilbur, D. S. et al., "Development of a Stable Radioiodinating Reagent to Label Monoclonal Antibodies for Radiotherapy of Cancer," <i>Journal of Nuclear Medicine</i> (1989) 30:216-226.	
	A13	Stein, R. et al., "Murine Monoclonal Antibodies Raised Against Human Non-Small Cell Carcinoma of the Lung: Specificity and Tumor Targeting," <i>Cancer Research</i> (February 1990) 50:1330-1336.	
	A14	Stein, R. et al., "Effects of Radiolabeling Monoclonal Antibodies with a Residualizing Iodine Radioisotope on the Accretion of Radioisotope in Tumors," <i>Cancer Research</i> (July 1995) 55:3132-3139.	
	A15	Govindan, S. V., et al., "Thiolations, <sup>99m</sup> Tc Labelings, and Animal <i>In Vivo</i> Biodistributions of Divalent Monoclonal Antibody Fragments," <i>Bioconjugate Chem.</i> (1996) 7:290-297.	
	A16	Hansen, H. J. et al., "Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen," <i>Cancer</i> (June 1993) 71(11):3478-3485.	
	A17	Devys et al., "Comparative Targeting of Human Colon-Carcinoma Multicell Spheroids Using One- and Two-step (Bispecific Antibody) Techniques," <i>Chemical Abstracts</i> (1996) 125(23):883-891.	
	A18	Bianchi, C. P., <i>Chemical Abstracts, 1-Pharmacology</i> (1988) 1:404-405.	
	A19	Govindan et al., "Labeling of Monoclonal Antibodies with Diethyltriaminepentaacetic Acid-Appended Radioiodinated Peptides Containing D-Amino Acids" <i>Bioconjugate Chemistry</i> (1999) 10:231-240	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.